Mechanisms of virologic failure in previously untreated HIV-infected patients 412 from a trial of induction-maintenance therapy. Trilege (Agence Nationale de 413 Recherches sur le SIDA 072) Study Team), JAMA, vol.411, issue.2, pp.205-211, 2000. ,
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection, Annals of Internal Medicine, vol.133, issue.1, pp.21-302109, 2000. ,
DOI : 10.7326/0003-4819-133-1-200007040-00004
Non-adherence to highly active antiretroviral therapy predicts 421 progression to AIDS, AIDS Bangsberg DR, vol.15, issue.5, pp.1181-1183, 2001. ,
Adherence to protease inhibitors, HIV- 424 1 viral load, and development of drug resistance in an indigent population, AIDS 425, vol.14, issue.6, pp.357-366, 2000. ,
Impact of a Patient Education Program on Adherence to HIV Medication, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.34, issue.2, pp.191-194, 2003. ,
DOI : 10.1097/00126334-200310010-00009
Better Adherence with Once???Daily Antiretroviral Regimens: A Meta???Analysis, Clinical Infectious Diseases, vol.48, issue.4, pp.484-488, 2009. ,
DOI : 10.1086/596482
Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research, AIDS, vol.25, issue.3, pp.279-290, 2011. ,
DOI : 10.1097/QAD.0b013e328340feb0
The dynamic of adherence to highly active antiretroviral 436 therapy: results from the French National APROCO cohort, J Acquir Immune Defic 437 Syndr Glass TR, vol.28, issue.10, pp.232-239, 2001. ,
440 Longitudinal analysis of patterns and predictors of changes in self-reported adherence 441 to antiretroviral therapy: Swiss HIV Cohort Study, J Acquir Immune Defic Syndr, vol.442, issue.443, pp.197-203, 2010. ,
Not all missed doses are the same: sustained NNRTI treatment 445 interruptions predict HIV rebound at low-to-moderate adherence levels, PLoS One, vol.446, issue.3, pp.2783-447, 2008. ,
Average 449 adherence to boosted protease inhibitor therapy, rather than the pattern of missed 450 doses, as a predictor of HIV RNA replication, Clin Infect Dis, vol.50, issue.451, pp.1192-1197, 2010. ,
Patterns of adherence to raltegravir-based regimens and the risk of 453 virological failure among HIV-infected patients: the RALTECAPS cohort study, p.454, 2012. ,
Time patterns of adherence and long-term virological response to non- 458 nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 459 12110/ESTHER trial in Cameroon. Antivir Ther, p.15, 2013. ,
Atazanavir 462 concentration in hair is the strongest predictor of outcomes on antiretroviral therapy, Clin Infect Dis, vol.463, issue.464, pp.1267-1275, 2011. ,
Patterns of adherence with 465 antiretroviral medications: an examination of between-medication differences, p.466, 2001. ,
HIV-infected 468 patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of 469 virologic suppression despite adherence rates less than 95%, J Acquir Immune Defic, vol.470, issue.471, pp.4-8, 2007. ,
Differential 473 adherence to combination antiretroviral therapy is associated with virological failure 474 with resistance, AIDS, vol.22, issue.475, pp.75-82, 2008. ,
Measurement of Adherence to Antiretroviral Medications, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.31, issue.21, pp.103-106616, 2002. ,
DOI : 10.1097/00126334-200212153-00003
485 Modelling the association between adherence and viral load in HIV-infected patients, Pharmacol Ther, vol.92, pp.575-83, 2005. ,
Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients, Journal of The Royal Society Interface, vol.2, issue.4, pp.349-363, 2005. ,
DOI : 10.1098/rsif.2005.0037
A comparison study of 493 multiple measures of adherence to HIV protease inhibitors, Ann Intern Med, vol.134, issue.495, pp.968-494, 2001. ,
Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy, AIDS, vol.19, issue.15, pp.1700-1702, 2005. ,
DOI : 10.1097/01.aids.0000186826.60983.85
Bilirubin-a potential marker of drug exposure 500 in atazanavir-based antiretroviral therapy, AAPS J, vol.13, issue.501, pp.598-605, 2011. ,
503 External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of 504, 2012. ,
Assessment of adherence to 506 antiviral therapy in HIV-infected children using the Medication Event Monitoring 507, 2003. ,
provider assessment, caregiver self-report, and appointment 508 keeping, J Acquir Immune Defic Syndr, vol.33, issue.509, pp.211-218, 2010. ,
Less Than 95% Adherence to Nonnucleoside Reverse???Transcriptase Inhibitor Therapy Can Lead to Viral Suppression, Clinical Infectious Diseases, vol.43, issue.7, pp.939-520, 2006. ,
DOI : 10.1086/507526
526 Repeated measures longitudinal analyses of HIV virologic response as a function of 527 percent adherence, dose timing, genotypic sensitivity, and other factors, J Acquir Immune Defic Syndr Gill CJ, vol.528, issue.34, pp.315-322, 2006. ,
Importance of dose timing to achieving undetectable viral loads. 531, AIDS Behav, vol.14, issue.532, pp.785-793, 2010. ,
Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir, Clinical Pharmacokinetics, vol.63, issue.7, pp.1035-534, 2005. ,
DOI : 10.2165/00003088-200544100-00003
Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease Inhibitor Therapy, HIV Clinical Trials, vol.2001134, issue.3, pp.135-142, 2009. ,
DOI : 10.7326/0003-4819-133-1-200007040-00004
Is Percentage Adherence Enough? 540 Correlation of the Various Adherence Metrics from the MACH14 Study, 7th 541 International Conference on HIV Treatment and Prevention Adherence, p.542 ,
Prevention of HIV-1 553 infection with early antiretroviral therapy, N Engl J Med, vol.365, pp.493-505, 2011. ,
Determinants of virological failure after successful viral load 556 suppression in first-line highly active antiretroviral therapy, Antivir Ther, vol.13, issue.557, pp.927-936, 2008. ,
Validation of the CNS Penetration-Effectiveness rank for quantifying 560 antiretroviral penetration into the central nervous system, Arch Neurol, vol.65, issue.561, pp.65-70, 2008. ,
McClelland 563 RS Antiretroviral adherence and development of drug resistance are the 564 strongest predictors of genital HIV-1 shedding among women initiating treatment, J 565 Infect Dis, vol.202, issue.566, pp.1538-1542, 2010. ,
Guidelines for Improving Entry Into and Retention in Care and 570, 2012. ,